Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.74 |
| ▸ | TNF | P01375 | 9/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL860004 | 1.00 | RIPK1 (0.74) | RIPK1TNFKMT2AL3MBTL1MEN1 | |
| SCHEMBL9945430 | 0.90 | RIPK1 (0.70) | RIPK1TNFKMT2AL3MBTL1MEN1 | |
| SCHEMBL17399987 | 0.89 | RIPK1 (0.72) | RIPK1TNFKMT2AL3MBTL1MEN1 | |
| SCHEMBL17830374 | 0.86 | TNF (0.82) | RIPK1TNFKMT2AL3MBTL1MEN1 | |
| SCHEMBL17471693 | 0.86 | RIPK1 (0.71) | RIPK1TNFKMT2AL3MBTL1MEN1 | |
| SCHEMBL17830339 | 0.85 | TNF (0.81) | RIPK1TNFKMT2AL3MBTL1MEN1 | |
| SCHEMBL17830389 | 0.85 | TNF (0.81) | RIPK1TNFKMT2AL3MBTL1MEN1 | |
| SCHEMBL859956 | 0.85 | RIPK1 (1.00) | RIPK1TNFKMT2AL3MBTL1MEN1 | |
| SCHEMBL860317 | 0.85 | RIPK1 (1.00) | RIPK1TNFKMT2AL3MBTL1MEN1 | |
| SCHEMBL29362205 | 0.85 | RIPK1 (1.00) | RIPK1TNFKMT2AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190023690-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2019-01-24 | — | — | US | disclosed |
| US-9944628-B2 | Inhibitors of cellular necrosis and related methods | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023690-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | LITAF, TNF, MMP8 | RIPK1 198/4885TNF 2/4885KMT2A 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.